# US 2015/0105322 A1 · Non-N-Glycosylated Recombinant Human Annexin A2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105322 A1
- Document ID: US20150105322A1
- Status: Published application
- Kind: A1
- Application number: 14/351,008
- Filed: 2012-10-11
- Published: 2015-04-16
- Earliest claimed: 2011-10-12
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: Zhirui Wang
- Web page: https://patentgrep.com/patent/US20150105322A1

## CPC

- A61K 38/1709: {from mammals}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K 14/47: from mammals
- C07K 14/4721: {Lipocortins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/21: containing a His-tag
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods for the expression and purification of non-N-glycosylated human Annexin A2 in yeast, e.g., in Pichia pastoris, purified Annexin A2 produced by those methods, and methods of using the Annexin A2.

## Claims

### Claim 1

A non-N-glycosylated human annexin A2 comprising SEQ ID NO:1, wherein the amino acid at position 62 is not Asparagine (N), and/or the amino acid at position 64 is neither Threonine (T) nor Serine (S).

### Claim 2 (depends on 1)

The non-N-glycosylated human annexin A2 of claim 1, wherein the amino acid at position 62 is Alanine (A) or Glycine (G).

### Claim 3 (depends on 1)

A codon-optimized nucleic acid molecule, preferably comprising SEQ ID NO: 2, encoding the non-N-glycosylated human annexin A2 of claim 1.

### Claim 4 (depends on 3)

A vector comprising the nucleic acid molecule of claim 3.

### Claim 5 (depends on 3)

A host cell expressing the nucleic acid molecule of claim 3.

### Claim 6 (depends on 5)

The host cell of claim 5, wherein the host cell is a methylotropic yeast.

### Claim 7 (depends on 6)

The host cell of claim 6, wherein the host cell is a cell of the species Pichia Pastoris.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising the non-N-glycosylated human annexin A2 of claim 1 and a physiologically acceptable carrier.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, further comprising an additional active agent.

### Claim 10 (depends on 1)

A method of treating a subject who has a vascular disorder associated with thrombus formation, the method comprising administering to the subject a therapeutically effective amount of the non-N-glycosylated human annexin A2 of claim 1.

### Claim 11 (depends on 10)

The method of claim 10, wherein the vascular disorder associated with thrombus formation is selected from the group consisting of ischemic stroke, cerebral venous thrombosis (CVT), myocardial infarction (MI), deep vein thrombosis (DVT), pulmonary embolism (PE), peripheral arterial disease (PAD), and blocked catheters.

### Claim 12 (depends on 1)

The non-N-glycosylated human annexin A2 of claim 1 for use in treating a vascular disorder associated with thrombus formation.

### Claim 13 (depends on 1)

Use of the non-N-glycosylated human annexin A2 of claim 1 in the manufacture of a medicament for treating a vascular disorder associated with thrombus formation.

### Claim 14 (depends on 12)

The annexin of claim 12, wherein the vascular disorder associated with thrombus formation is selected from the group consisting of ischemic stroke, cerebral venous thrombosis (CVT), myocardial infarction (MI), deep vein thrombosis (DVT), pulmonary embolism (PE), peripheral arterial disease (PAD), and blocked catheters.

### Claim 15

A method of producing a non-N-glycosylated human annexin A2, the method comprising:
expressing a non-N-glycosylated human annexin A2 comprising SEQ ID NO:1, wherein the amino acid at position 62 is not Asparagine (N), and/or the amino acid at position 64 is neither Threonine (T) nor Serine (S), in a methylotropic yeast; and
substantially purifying the non-N-glycosylated human annexin A2,
thereby producing the composition.

### Claim 16 (depends on 15)

The method of claim 15, wherein substantially purifying the non-N-glycosylated human annexin A2 comprises:
contacting a composition comprising non-N-glycosylated human annexin A2 with a strong cation exchange resin; and
collecting fractions having higher annexin 2 biological activity.

### Claim 17 (depends on 16)

The method of claim 16, comprising collecting one or both of a flow-through and a washing fraction.
